<DOC>
	<DOCNO>NCT02116764</DOCNO>
	<brief_summary>This study longitudinal cross-sectional evaluation patient Chronic Granulomatous Disease ( CGD ) receive receive hematopoietic cell transplantation ( HCT ) disease variety protocol use participate institution compare control non-HCT group receive standard care . Investigators multiple center care patient CGD North America 3 center Europe participate . Patients CGD treat accord institutional practice protocol . Investigators enroll patient subject protocol . This study investigate patient benefit HCT , type transplant optimal patient CGD , context overall outcome CGD patient without transplant .</brief_summary>
	<brief_title>Analysis Patients Treated Chronic Granulomatous Disease Since January 1 , 1995</brief_title>
	<detailed_description>This study longitudinal cross-sectional evaluation patient Chronic Granulomatous Disease ( CGD ) receive receive hematopoietic cell transplantation ( HCT ) disease variety protocol use participate institution compare control non-HCT group receive standard care . Investigators multiple center care patient CGD North America 3 center Europe participate . Patients CGD treat accord institutional practice protocol . Investigators enroll patient subject protocol . This study investigate patient benefit HCT , type transplant optimal patient CGD , context overall outcome CGD patient without transplant .</detailed_description>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>Both HCT nonHCT subject must age 2 actively enrol receive treatment CGD protocol NIAID .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 30, 2017</verification_date>
	<keyword>Hematopoietic ( Stem ) Cell Transplantation</keyword>
	<keyword>Primary Immune Deficiency Consortium</keyword>
</DOC>